FCGR2A and cancer: Targeting cancer-derived IgG or blocking FCGR2A could potentially hinder TEP-mediated metastasis and may offer a novel therapeutic strategy for inhibiting cancer-induced platelet activation while minimizing disruption to normal hemostatic processes.